Barrier Therapeutics Announces Azoline (Pramiconazole) Dose Ranging Study in Tinea Versicolor Meets Primary and Secondary Endpoints Oral Formulation of Novel Antifungal Agent Shown to Be Highly Effective PRINCETON, NJ, Mar 27, 2007 (MARKET WIRE via COMTEX News...
Intarcia Therapeutics Announces Final Results From A Phase 2 Study Of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1 Potent synergy, activity and patient tolerance support development of Omega DUROS® continuous delivery therapy...
Affymax(R) Announces Results From Phase 2 Clinical Trial of Hematide(TM) for the Treatment of Anemia in Dialysis Patients PALO ALTO, Calif., Apr 12, 2007 (BUSINESS WIRE) — Affymax, Inc. (Nasdaq:AFFY) today announced that results available from its Phase 2...
Affymax® Announces Phase 3 Development Plan for Hematide™ PALO ALTO, Calif., Jul 16, 2007 (BUSINESS WIRE) — Affymax, Inc. (Nasdaq:AFFY) today announced that it plans to initiate Phase 3 clinical studies with Hematide(TM) in chronic renal failure patients...
Prometheus Laboratories Plans IPO NEW YORK – 12.19.07 – Prometheus Laboratories Inc., which is developing diagnostic tests and drugs to help doctors individualize patient care, plans an initial public offering of common stock, according to a Securities and...
Recent Comments